CELZ CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

CIK 0001187953 27 ready 8-Ks latest August 31, 2026, 4:05 PM ET RSS · JSON

Activity: NORMAL 1 filings / 30d vs 0 baseline

Ready 8-Ks 27

Latest filing August 31, 2026, 4:05 PM ET

Top materiality 0.75

Event mix other_material ×18 · other ×3 · regulatory ×3

Sentiment 2 pos · 2 neg · 23 neu

Executive change recent →

SHENANIGAN SCORE 1 / 7 see the board

Recent 8-K filings for CELZ

Highest-materiality recent filing

Creative Medical regains Nasdaq minimum bid price compliance after 10-day stretch above $1.00

June 28, 2023, 7:59 PM ET regulatory materiality 0.75 positive item 8.01 item 9.01

Received Nasdaq notice on June 27, 2023 that it regained compliance with Listing Rule 5550(a)(2).
Closing bid price exceeded $1.00 for 10 consecutive trading days (June 12–26, 2023).

Read filing →

August 31, 2026, 4:05 PM ET other materiality 0.30 neutral item 5.03 item 5.07 item 9.01

Creative Medical shareholders approve share increase to 100M and full warrant exercise

Authorized shares increased from 25M to 100M via Certificate of Amendment filed in Nevada on Aug 28, 2026.
July 2, 2026, 4:15 PM ET other material materiality 0.60 neutral item 1.01 item 3.02 item 5.02 item 9.01

Creative Medical raises ~$4.5M via warrant exercise inducement; issues new warrants for 5.58M shares

Existing warrants for 2.79M shares exercised at reduced price of $1.60/share, raising ~$4.5M gross proceeds.
December 31, 2025, 6:59 PM ET other material materiality 0.15 neutral item 5.07 item 9.01

Shareholders approve exercise of warrants for 2.79M shares of Creative Medical Technology

Warrants to purchase 2,790,340 shares issued Oct 29, 2025, approved at Dec 26 special meeting.
December 19, 2025, 6:59 PM ET other materiality 0.15 neutral item 5.07 item 9.01

All five director nominees elected at 2025 annual meeting; say-on-pay and auditor ratified

Five director nominees elected: For votes 419,951–434,837; withhold votes under 57,000 each.
November 12, 2025, 6:59 PM ET leadership materiality 0.30 neutral item 5.02 item 9.01

Creative Medical Technology Holdings approves $100k CEO and $25k CFO bonuses

Compensation Committee approved bonuses on November 6, 2025
October 31, 2025, 7:59 PM ET other material materiality 0.70 neutral item 1.01 item 3.02 item 9.01 ◈ Equity Issuances

CELZ raises ~$4.2M via warrant exercise inducement; issues 2.79M new warrants

Holders of 1,116,136 warrants exercised at $3.75/share, yielding $4.2M gross proceeds.
May 6, 2025, 7:59 PM ET other material materiality 0.15 neutral item 5.07 item 9.01

Stockholders approve exercise of warrants for 1.8M shares at special meeting

Special meeting on May 5, 2025; 35% quorum (813,562 shares) present.
April 11, 2025, 7:59 PM ET regulatory materiality 0.35 neutral item 3.01 item 9.01 ◈ Listing & Compliance Notices

Creative Medical receives Nasdaq notice for late clawback policy adoption; matter closed as now compliant.

On April 8, 2025, Nasdaq notified Creative Medical for failure to timely adopt and disclose Clawback Policy per Listing Rule 5608.
March 14, 2025, 7:59 PM ET other material materiality 0.40 neutral item 5.02 item 9.01

Creative Medical Tech awards $100k in bonuses to CEO and CFO

CEO Timothy Warbington received a $70,000 bonus approved March 10, 2025.
March 7, 2025, 6:59 PM ET other material materiality 0.65 neutral item 1.01 item 3.02 item 9.01

Creative Medical Technology raises $3.7M via warrant exercise inducement; issues new warrants at $3.75

Gross proceeds of ~$3.7M from cash exercise of 837,104 existing warrants at $4.42/share.
December 26, 2024, 6:59 PM ET other material materiality 0.60 neutral item 5.03 item 5.07 item 9.01 ◈ Governance Changes

Shareholders vote to increase authorized shares from 5M to 25M, approve warrant exercise

Authorized common shares increased from 5M to 25M via Certificate of Amendment filed Dec 19, 2024.
October 23, 2024, 7:59 PM ET other material materiality 0.60 neutral item 1.01 item 9.01

CELZ raises $1.85M in registered direct offering of shares and warrants

Gross proceeds ~$1.85M; net ~$1.6M after fees and expenses; proceeds for working capital.
July 25, 2024, 7:59 PM ET other material materiality 0.15 negative item 5.07 item 9.01

Creative Medical Technology Holds 2024 Annual Meeting; Say-on-Pay Vote Fails

Five director nominees elected; Timothy Warbington and others received >300K votes for vs ~147K withhold.
May 17, 2024, 7:59 PM ET other material materiality 0.50 neutral item 1.01 item 3.02 item 3.03 item 5.03 item 5.08 item 9.01

CEO buys one Series B Preferred share with special voting rights on share increase; annual meeting July 19

CEO Timothy Warbington purchased one Series B Preferred share for $100; it carries 100M votes on share increase proposal.
December 20, 2023, 6:59 PM ET other material materiality 0.15 neutral item 5.07 item 9.01 ◈ Shareholder Votes ×3

Shareholders elect all five director nominees and approve say-on-pay at annual meeting

Quorum of 55.9% (776,982 shares) present at December 20, 2023 annual meeting.
June 28, 2023, 7:59 PM ET regulatory materiality 0.75 positive item 8.01 item 9.01

Creative Medical regains Nasdaq minimum bid price compliance after 10-day stretch above $1.00

Received Nasdaq notice on June 27, 2023 that it regained compliance with Listing Rule 5550(a)(2).
June 9, 2023, 7:59 PM ET other material materiality 0.60 neutral item 3.03 item 5.03 item 8.01 item 9.01 ◈ Governance Changes

Creative Medical Technology announces 1-for-10 reverse stock split effective June 12, 2023 to regain Nasdaq compliance

Reverse split ratio 1-for-10; outstanding shares reduced from ~14.1M to ~1.4M.
December 19, 2022, 6:59 PM ET other materiality 0.15 neutral item 5.07 item 9.01 ◈ Shareholder Votes ×4

Creative Medical Technology shareholders elect all directors, approve executive compensation and auditor ratification

Seven directors elected with votes ranging from 2,675,852 to 2,694,252 in favor; no withhold above 361,796.
July 14, 2022, 7:59 PM ET regulatory materiality 0.65 negative item 3.01

Creative Medical receives Nasdaq deficiency notice for bid price below $1.00

Nasdaq notice for non-compliance with Listing Rule 5550(a)(2) due to bid price below $1.00 for 30 consecutive days.
May 4, 2022, 7:59 PM ET other material materiality 0.70 neutral item 1.01 item 3.02 item 9.01

Creative Medical raises ~$17M in private placement with institutional investors

Company sold 2,991,669 shares, 4,563,887 pre-funded warrants ($0.0001 exercise), and 15,111,112 common warrants ($2.00; 5-year term) at $2.25 per combined unit.
May 4, 2022, 7:59 PM ET other material materiality 0.75 neutral item 1.01 item 3.02 item 9.01

Creative Medical raises $17M in PIPE with shares, pre-funded & common warrants

Gross proceeds ~$17M from sale of 2,991,669 shares, pre-funded warrants for 4,563,887 shares, and common warrants for 15,111,112 shares at $2.25/unit.
February 11, 2022, 6:59 PM ET leadership materiality 0.50 neutral item 5.02 item 9.01

Creative Medical enters new 3-year employment agreements with CEO and CFO

CEO Warbington base salary $330,000/year; CFO Dickerson $300,000/year.
December 7, 2021, 6:59 PM ET other material materiality 0.75 positive item 1.01 item 3.01 item 5.02 item 9.01 ◈ executive_change ×5

Creative Medical Technology Holdings prices $16M public offering, uplists to Nasdaq, appoints new directors

Priced 3.875M shares and warrants at $4.13 per combined unit; gross proceeds ~$16M.
November 9, 2021, 6:59 PM ET other material materiality 0.70 neutral item 3.03 item 5.03 item 8.01 item 9.01

Creative Medical announces 1-for-500 reverse stock split; authorized shares cut to 50M

Reverse split at 1:500 effective Nov 10, 2021; outstanding shares reduced from ~1.23B to ~2.45M.
November 5, 2021, 7:59 PM ET other material materiality 0.65 neutral item 3.03 item 5.03 item 9.01

Creative Medical increases authorized common shares from 6B to 25B; withdraws Series B and C Preferred designations

Authorized common shares increased from 6,000,000,000 to 25,000,000,000 via Certificate of Amendment filed Nov 2, 2021.
September 22, 2021, 7:59 PM ET other material materiality 0.30 neutral item 5.02

Creative Medical enters direct employment with CEO, CFO, consultants; ends reimbursement agreement

CEO Timothy Warbington receives $330k annual base salary effective 9/16/2021.
August 12, 2021, 7:59 PM ET debt materiality 0.55 neutral item 1.01 item 2.03 item 3.02 item 9.01

Creative Medical raises ~$3.8M via 15% OID senior notes and warrants

Sold $4,456,176 principal amount of 15% OID senior notes for $3,787,750 in cash.